tradingkey.logo
tradingkey.logo
Search

Aethlon Medical Inc

AEMD
Add to Watchlist
5.290USD
-0.150-2.76%
Close 11-02 16:00(ET)
8.46MMarket Cap
LossP/E TTM
Pre-market 06:50 (ET)5.675USD+0.385+7.28%

About Aethlon Medical Inc Company

Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Aethlon Medical Inc Profile

Ticker SymbolAEMD
Company nameAethlon Medical Inc
IPO dateMar 09, 1994
CEOFrakes (James B)
Number of employees9
Security typeOrdinary Share
Fiscal year-endMar 09
Address11555 Sorrento Valley Road, Suite 203
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone16199410360
Websitehttps://www.aethlonmedical.com/
Ticker SymbolAEMD
IPO dateMar 09, 1994
CEOFrakes (James B)

Company Executives of Aethlon Medical Inc

Name
Name/Position
Position
Shareholding
Change
Mr. James B. (Jim) Frakes
Mr. James B. (Jim) Frakes
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
42.00K
+100.00%
Mr. Steven P. Larosa, M.D.
Mr. Steven P. Larosa, M.D.
Chief Medical Officer
Chief Medical Officer
42.00K
--
Ms. Angela Rossetti
Ms. Angela Rossetti
Independent Director
Independent Director
1.57K
-554.67%
Mr. Edward G. Broenniman
Mr. Edward G. Broenniman
Independent Chairman of the Board
Independent Chairman of the Board
1.04K
-20.98%
Dr. Chetan S. Shah, M.D.
Dr. Chetan S. Shah, M.D.
Independent Director
Independent Director
512.00
-85.16%
Mr. Nicolas Gikakis
Mr. Nicolas Gikakis
Independent Director
Independent Director
512.00
-85.16%
Ms. Susan Noonan
Ms. Susan Noonan
Managing Partner, Investor Relations
Managing Partner, Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James B. (Jim) Frakes
Mr. James B. (Jim) Frakes
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
42.00K
+100.00%
Mr. Steven P. Larosa, M.D.
Mr. Steven P. Larosa, M.D.
Chief Medical Officer
Chief Medical Officer
42.00K
--
Ms. Angela Rossetti
Ms. Angela Rossetti
Independent Director
Independent Director
1.57K
-554.67%
Mr. Edward G. Broenniman
Mr. Edward G. Broenniman
Independent Chairman of the Board
Independent Chairman of the Board
1.04K
-20.98%
Dr. Chetan S. Shah, M.D.
Dr. Chetan S. Shah, M.D.
Independent Director
Independent Director
512.00
-85.16%
Mr. Nicolas Gikakis
Mr. Nicolas Gikakis
Independent Director
Independent Director
512.00
-85.16%

FAQs

Who are the top five shareholders of Aethlon Medical Inc?

The top five shareholders of Aethlon Medical Inc are: Mr. James B. (Jim) Frakes

How many institutions hold shares of Aethlon Medical Inc (AEMD)?

As of 2026Q1, 37 institutions hold shares of Aethlon Medical Inc, with a combined market value of approximately 101.87K, accounting for 6.49% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 42952.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.